Positron emission tomography (PET) imaging of Alzheimers Disease (AD) offers the potential to provide early onset diagnosis and subsequent intervention, including guided treatment regimens. One of the restricting factors in clinical application of PET technology is the limited availability of radioligands with affinity to specific targets of interest. Given the short half-life of the most popular positron emitter currently used (18F; ∼120 min.) extremely rapid and efficient radiochemistry methods are needed to ensure required compounds are prepared and purified for administration within the 2-3 half life practical limit. Recent efforts to combine microwave mediated synthesis with advanced catalysis in the synthesis of specific categories of AD imaging agents will be presented.
Keywords: F18, PET, imaging agents, microwave, synthesis, radiochemistry
Rights & PermissionsPrintExport